SCHEMBL26620398

SCHEMBL26620398

O=C(O)COc1cc(-c2ccccc2)ccc1N1CCC(Oc2ccc(C(F)(F)F)cn2)C1

nearest known ligand 0.64

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ LIPG Q9Y5X9 11/20 0.64
▸ LIPE Q05469 8/20 0.46
▸ LPL P06858 5/20 0.46
▸ LIPC P11150 4/20 0.45
▸ PTGDR2 Q9Y5Y4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23702852 1.00 LIPG (0.64) LIPGLIPELPLLIPCPTGDR2
SCHEMBL23702939 0.91 LIPG (0.61) LIPGLIPELPLLIPC
SCHEMBL29994487 0.91 LIPG (0.61) LIPGLIPELPLLIPC
SCHEMBL23708105 0.91 LIPG (0.61) LIPGLIPELPLLIPC
SCHEMBL23708323 0.91 LIPG (0.61) LIPGLIPELPLLIPC
SCHEMBL29935833 0.91 LIPG (0.61) LIPGLIPELPLLIPC
SCHEMBL29935380 0.90 LIPG (0.61) LIPGLIPELPLLIPC
SCHEMBL28887165 0.90 LIPG (0.61) LIPGLIPELPLLIPC
SCHEMBL23708143 0.90 LIPG (0.61) LIPGLIPELPLLIPC
SCHEMBL23702984 0.90 LIPG (0.58) LIPGLIPELPLLIPCPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115335050-B Compounds and compositions for treating skin disorders 卡玛瑞制药有限公司 2024-05-17 — — CN disclosed
US-20240124413-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS KAMARI PHARMA LTD. (IL) 2024-04-18 — — US disclosed
US-11807621-B2 Compounds and compositions for use in treating skin disorders KAMARI PHARMA LTD. (IL) 2023-11-07 — — US disclosed
CN-115335050-A Compounds and compositions for treating skin conditions 卡玛瑞制药有限公司 2022-11-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124413-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS RDX, HAX1, F12 LIPG 1423/4885LIPE 3173/4885LPL 3701/4885
US-11807621-B2 Compounds and compositions for use in treating skin disorders RDX, HAX1, F12 LIPG 1423/4885LIPE 3173/4885LPL 3701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback